Table 2.
Natural Products/Extract | Strategy for Bioavailability Augmentations | Conc./ Dose |
Bioavailability Enhancement (Effect of ADMET) | Effect on Oral Cancer | Mechanisms | Reference | |
---|---|---|---|---|---|---|---|
Bioavailability of Normal Drug | Bioavailability of Novel Formulation | ||||||
Capsaicin | SNEDDS | 305.41 g/mol | 16.61 ± 3.64% | 3.6-fold increase in bioavailability | Antiproliferative effects | MMP disruption, caspase-3, caspase-7 and caspase-9 activation through an intrinsic apoptotic pathway and subsequently, apoptotic DNA fragmentation | [186] |
EGCG | NE | 200–800 mg | NR | The bioavailability was more than 2.78-fold | Inhibition of both cell proliferation and migration | Targets multiple signaling pathways, including the downregulation of EGFR and associated downstream signaling molecules | [187,188,189,190] |
Piperlongumine | NPs | 7.4–11.3 μM | NR | NR | Antiproliferative effects, cell cycle arrest and senescence | ↓PI3K/Akt/mTOR pathway, ↓ROS, ↑apoptosis, ↑G1 phase cell cycle arrest, ↑p21, ↑cleaved caspases-3, ↑PARP | [191,192] |
Bromelain | Lipid-polymer hybrid nanoparticles | 12.5–100 µg mL | NR | Maximum release of Bromelain from nanocarriers was obtained 30–35% after 5 days | Inhibited cell growth and proliferation | G1 cell cycle arrest, induced apoptosis | [26,193,194,195] |
Curcumin | Curcumin nanocrystals/NPs | 10 or 12 g/mL | 1% | Over 5 times from simple curcumin powder | Inhibit growth, invasion and metastasis | Inhibits the invasive ability and EMT by reducing the MMP-2 and MMP-9 expression, downregulation of EGFR expression | [196] |
Berberine | Vitamin E d-α-tocopheryl polyethylene glycol 1000 succinate-mixed polymeric phospholipid micelles of berberine | 100 or 300 mg/kg | <5% in plasma | 15% | Antimitotic and proapoptotic actions, along with distinct antiangiogenic and antimetastatic activities | Suppresses the mRNA expression of NFKB1 and PTGS2 and AURKA, BIRC5, and EGFR | [26,197] |
Honokiol | NPs | 0–150 mg/kg | NR | 53% of honokiol was released from the nanoparticles within 24 h | Antiproliferative effect | Blocks EMT through the modulation of Snail/Slug protein translation | [198] |
Evodiamine | Nanocomposite system comprising folic acid- modified graphene quantum dots |
1 mg | NR | Over 90% of drug was released in 72 h |
Inhibited cell proliferation |
Downregulates Mcl-1 expression, induces apoptosis mediated by a caspase-dependent pathway |
[199] |
Gedunin | Chitosan- encapsulated gedunin |
1.5–50 µg/mL |
NR | NR | 3 to 8-fold decrease |
Modulates AR, PI3K/Akt, and NF-κB pathways to block angiogenesis | [200] |
Sinularin | Not found | NR | NR | NR | Selectively kill the oral cancer cells |
Antiproliferative and apoptotic effects on oral cancer cells coupled with ROS generation and G2/M arrest |
[201] |
Abbreviations: AR, aldose reductase; AURKA, aurora kinase A; EGCG, epigallocatechin gallate; EGFR, epidermal growth factor receptor; EMT, epithelial-mesenchymal transition;; MMP, mitochondrial membrane potential; NF-κB, nuclear factor-κB; PARP, poly adenosine diphosphate-ribose polymerase; PI3K, phosphatidyl inositol-3-kinase; PTGS2, prostaglandin coding gene; ROS, reactive oxygen species; SNEDDS, self-nano emulsifying drug delivery system.